Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with mFOLFOX6 vs Bevacizumab with FOLFIRI in first-line metastatic colorectal cancer
2011-004755-39Phase 2Completed
- Sponsor
- Genentech
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in metastatic colon cancer (mCRC) (2 arms), sponsored by Genentech. Primary endpoint: Progression-free survival. Started Apr 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2011-004755-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004755-39.